BALICATIB

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C23H33N5O2
Molecular Weight	411.5404
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3(CCCCC3)C(=O)NCC#N

InChI

InChIKey=LLCRBOWRJOUJAE-UHFFFAOYSA-N

InChI=1S/C23H33N5O2/c1-2-14-27-15-17-28(18-16-27)20-8-6-19(7-9-20)21(29)26-23(10-4-3-5-11-23)22(30)25-13-12-24/h6-9H,2-5,10-11,13-18H2,1H3,(H,25,30)(H,26,29)

HIDE SMILES / InChI

Molecular Formula	C23H33N5O2
Molecular Weight	411.5404
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: www.ncbi.nlm.nih.gov/pubmed/26297834 | https://www.novartis.com/sites/www.novartis.com/files/Novartis-20-F-2004.pdf

Balicatib is a potent cathepsine K inhibitor that was developed for the treatment of knee osteoarthritis. The development of Balicatib was terminated in phase II due to the occurrence of skin rashes and rarer incidences of morphea-like skin changes.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cathepsin K 4 Target ID: CHEMBL268 Sources: https://www.novartis.com/sites/www.novartis.com/files/Novartis-20-F-2004.pdf	Inhibitor 8504		1.4 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Osteoarthritis of knee 23 Sources: https://clinicaltrials.gov/ct2/show/NCT00371670	Primary		Phase II 1147	Unknown Approved Use Unknown

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252	inhibitor 2438	inhibitor 2507

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1741

Drug as perpetrator

Target	Modality	Activity
CYP2C9 2497	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1645842#sid=440681464	no
CYP2D6 2546	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1645840#sid=440681464	no
CYP3A4 2633	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1645841#sid=440681464	no
P-gp 1932	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1346987#sid=363678065	no

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P00C6V1	https://www.1pchem.com/search?query=1P00C6V1
AChemBlock	O33814	http://www.achemblock.com/catalogsearch/result/?q=O33814
Angene	AGN-PC-0WH9O8	http://www.angenechemical.com/productshow/AGN-PC-0WH9O8.html
ApexBio Technology	B3265	https://www.apexbt.com/catalogsearch/result/?q=B3265
AstaTech	41237	http://astatechinc.com/CPSResult.php?CRNO=41237
Axon MedChem	2154	https://www.axonmedchem.com/product/2154
BLD Pharm	BD448235	http://www.bldpharm.com/search/Search.html?keyword=BD448235
BOC Sciences	354813-19-7	http://www.bocsci.com/description.asp?cas=354813-19-7
Cayman Chemical	17995	http://www.caymanchem.com/app/template/Product.vm/catalog/17995
Chem Scene	CS-2623	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-2623
ChemShuttle	112007	https://www.chemshuttle.com/catalogsearch/result/?q=112007
Combi-Blocks	QJ-8646	http://www.combi-blocks.com/cgi-bin/find.cgi?QJ-8646
Debye Scientific	DA-35184	https://www.debyesci.com/index.php?id=product&ext[cno]=DA-35184
eMolecules	49435290	https://orderbb.emolecules.com/search/#?query=49435290
Excenen	EX-A362	http://www.excenen.com/searchresultlist.php?id=EX-A362
KeyOrganics	AS-56087	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-56087
Matrix Scientific	147315	http://www.matrixscientific.com/147315.html
mcule	MCULE-9764581797	https://mcule.com/MCULE-9764581797/
MedChem Express	HY-15100	https://www.medchemexpress.com/search.html?q=HY-15100&ft=&fa=&fp=
Molnova	M14213	https://www.molnova.com/en/serch-list.html?keywords=M14213
MolPort	MolPort-039-101-330	https://www.molport.com/shop/molecule-link/MolPort-039-101-330
MuseChem	I003294	https://www.musechem.com/product/I003294.html
Ryan Scientific	101-94123	https://ryansci.com/products?q=101-94123&list_q=&search_type=exact
Ryan Scientific	LDN212854	https://ryansci.com/products?q=LDN212854&list_q=&search_type=exact
ShangHai Biochempartner	BCP09098	http://www.biochempartner.com/search_BCP09098
TargetMol	T1850	https://www.targetmol.com/search?keyword=T1850
Tocris	5585	https://www.tocris.com/search.php?Type=QuickSearch&Value=5585
Toronto Research Chemicals	B115650	https://www.trc-canada.com/product-detail/?CatNum=B115650
Toronto Research Chemicals	F537558	https://www.trc-canada.com/product-detail/?CatNum=F537558

PubMed

Title	Date	PubMed
Emerging targets in osteoporosis disease modification.	2010-06-10	20218623

Patents

Sample Use Guides

In Vivo Use Guide

Patients receive 10, 25 or 50 mg tablets daily.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:44:49 GMT 2025` Edited by `admin` on `Mon Mar 31 18:44:49 GMT 2025`
Record UNII	E00MVC7O57
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AAE-581

Preferred Name

English

BALICATIB

Official Name

English

AAE581

Code

English

Balicatib [WHO-DD]

Common Name

English

N-(1-((CYANOMETHYL)CARBAMOYL)CYCLOHEXYL)-4-(4-PROPYLPIPERAZIN-1-YL)BENZAMIDE

Systematic Name

English

balicatib [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C67439